doi: 10.1161/hc0802.105564
(Circulation. 2002;105:904.)
© 2002 American Heart Association, Inc.
Brief Rapid Communications |
Targeting Phospholamban by Gene Transfer in Human Heart Failure
From the Cardiovascular Research Center, Massachusetts General Hospital, Heart Failure and Cardiac Transplantation Center (F.d.M., G.W.D., R.J.H.), Harvard Medical School (J.K.G.), Boston, Mass; and the National Heart and Lung Institute (S.E.H.), Imperial College, London, UK.
Correspondence to Roger J. Hajjar, MD, Massachusetts General Hospital, Cardiovascular Research Center, 149 13th St, CNY-4, 4215, Charlestown, MA 02129. E-mail rhajjar{at}partners.org
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— Myocardial cells from failing human hearts are characterized by abnormal calcium handling, a negative force-frequency relationship, and decreased sarcoplasmic reticulum Ca2+ ATPase (SERCA2a) activity. In this study, we tested whether contractile function can be improved by decreasing the inhibitory effects of phospholamban on SERCA2a with adenoviral gene transfer of antisense phospholamban (asPL).
Methods and Results— Myocardial cells isolated from 9 patients with end-stage heart failure and 18 donor nonfailing hearts were infected with adenoviruses encoding for either the antisense of phospholamban (Ad.asPL), the SERCA2a gene (Ad.SERCA2a), or the reporter genes ß-galactosidase and green fluorescent protein (Ad.ßgal-GFP). Adenoviral gene transfer with Ad.asPL decreased phospholamban expression over 48 hours, increasing the velocity of both contraction and relaxation. Compared with cardiomyocytes infected with Ad.asPL (n=13), human myocytes infected with Ad.ßgal-GFP (n=8) had enhanced contraction velocity (20.3±3.9% versus 8.7±2.6% shortening/second; P<0.01) and relaxation velocity (26.0±6.2% versus 8.6±4.3% shortening/second; P<0.01). The improvement in contraction and relaxation velocities was comparable to cardiomyocytes infected with Ad.SERCA2a. Failing human cardiomyocytes had decreased contraction and Ca2+ release with increasing frequency (0.1 to 2 Hz). Phospholamban ablation restored the frequency response in the failing cardiomyocytes to normal; increasing frequency resulted in enhanced sarcoplasmic reticulum Ca2+ release and contraction.
Conclusion— These results show that gene transfer of asPL can improve the contractile function in failing human myocardium. Targeting phospholamban may provide therapeutic benefits in human heart failure.
Key Words: calcium • heart failure • gene therapy
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Congestive heart failure has been intimately associated with abnormalities in intracellular [Ca2+] handling.1 In the failing heart, resting [Ca2+] is elevated, the amplitude of the [Ca2+] transient is decreased, and its duration is prolonged.2 These changes are the direct result of an abnormal sarcoplasmic reticulum (SR) Ca2+ ATPase pump (SERCA2a), the activity of which is reduced in heart failure.3–5 SERCA2a is regulated by phospholamban, the phosphorylation of which relieves the inhibition of SERCA2a. The phospholamban/SERCA2a interaction controls the calcium content of the SR and ultimately controls cardiac contractility.6,7 A decrease in the phosphorylation of phospholamban, along with an increase in the phoshpholamban/SERCA2a ratio, contributes to contractile dysfunction in heart failure.3,5 Contractility, calcium handling, and the frequency response were restored in isolated failing human cardiomyocytes by restoring this ratio by means of a gene transfer that caused the overexpression of SERCA2a.8 Another approach to restoring the phospholamban/SERCA2a ratio in failing hearts to normal would be to decrease levels of phospholamban through the use of antisense strategies.
In the present study, we have used such a strategy by generating adenoviral vectors expressing antisense of phospholamban and examining their effects on phospholamban expression, SERCA2a activity, and myocyte function in failing human cardiomyocytes.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Failing human ventricular myocardial tissue was obtained from 9 explanted hearts (5 ischemic and 4 with dilated cardiomyopathy), and nonfailing tissue was obtained from 18 donor hearts. Myocytes were isolated from 1 g of myocardial tissue removed from the free wall of the left ventricle by enzymatic digestion, as described previously.8 The proportion of rod-shaped viable cells at the time of isolation was 30% to 50% (n=9) for failing and 40% to 60% (n=18) for nonfailing cardiomyocytes. After isolation, the cells were resuspended in M199, 50 U/mL penicillin, and 50 U/mL streptomycin; equilibrated to pH 7.4; and infected with the adenoviruses at a multiplicity of infection of 100.
The antisense cDNA of phospholamban was first cloned into a shuttle vector, pAdTrack-CMV.9 The resultant plasmid was linearized with restriction endonuclease PmeI and subsequently was cotransformed into E coli BJ5183 cells with an adenoviral backbone plasmid, pAdEasy-1. Recombinants were selected for kanamycin resistance, and recombination was confirmed by multiple-restriction endonuclease analyses. The linearized recombinant plasmid was transfected into adenovirus-packaging cell lines (293 cells). Ad.ßgal-GFP, which contains both ß-galactosidase and green fluorescent protein (GFP) controlled by separate cytomegalovirus promoters, was used as control. Ad.SERCA2a, which carries both the SERCA2a and GFP genes, was also used.
Forty-eight hours after infection, myocytes were placed in a flow chamber on the stage of an inverted microscope, superfused with oxygenated Krebs-Henseleit solution, and electrically stimulated with biphasic pulse (0.2 Hz, 50% above threshold). Contraction amplitude and rates of contraction and relaxation were recorded online using a video-edge-detection system and data acquisition software (IonOptix). The fluorescent Ca2+ indicator Fura-2 (Molecular Probes) was used to measure intracellular Ca2+ through the use of a dual excitation spectrofluorometer (IonOptix), as described previously.8 Cumulative concentration-response experiments to isoproterenol, ranging from 0.01 nmol/L to 1 µmol/L, were performed. Cell shortening was measured at each dose and also at the maximum shortening response reached.
We isolated SR membranes from ventricular myocytes, and SERCA2a activity assays were carried out on the basis of Pyruvate/NADH-coupled reactions at [Ca2+] of 10 µmol/L, as previously described.8 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed on the isolated membranes under reducing conditions on a 7.5% to 12.5% separation gel with a 4% stacking gel, and membranes were immunoblotted with 1:2500 diluted monoclonal anti-phospholamban and anti-SERCA2 antibody (Affinity BioReagents, Golden, Colo). The blot was then incubated in a chemiluminescence system and exposed to an X-OMAT AR x-ray film (Fuji Films) for 1 minute. Data are presented as mean±SEM and were analyzed using a 1-way ANOVA, with statistical differences identified at P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The coexpression of GFP allowed us to identify the cells that were infected and expressing the transgene after 48 hours. Both nonfailing and failing cardiac cells infected with Ad.asPL showed a >50% decrease in the expression of phospholamban, as shown in Figure 1A. SERCA2a measured from failing cardiomyocytes showed a decrease compared with nonfailing cardiomyocytes. Both ablation of phospholamban and increased SERCA2a overexpression enhanced ATPase activities. However, the increase in ATPase activity was larger in cells overexpressing SERCA2a, as shown in Figure 1B. Figure 1C shows tracings from representative cardiomyocytes isolated from failing hearts, which are characterized by decreased shortening and prolonged relaxation when compared with the donor nonfailing cardiomyocytes. As shown in Table, ablation of phospholamban and overexpression of SERCA2a were associated with marked improvement in contraction, relaxation, and calcium handling. Ablation of phospholamban also restored the frequency response in failing cardiomyocytes (data not shown).
|
|
To examine whether ablation of phospholamban improves calcium handling in human cardiomyocytes, we increased extracellular calcium and measured contractile parameters. As shown in Figure 2A, ablation of phospholamban improved contraction and relaxation velocities to the same degree as did overexpression of SERCA2a at calcium levels up to 4 mmol/L. However, cells overexpressing SERCA2a were more tolerant to the higher calcium concentrations than were the cells infected with Ad.asPL.
|
(time course of relaxation as a function of increasing extracellular calcium), in human cardiomyocytes infected with Ad.asPL (n=6), Ad.SERCA2a (n=6) or Ad.ßgal-GFP (n=8). B, Tabulated effects of isoproterenol in human cardiomyocytes infected with either Ad.ßgal-GFP or Ad.asPL (control, n=5; +isoproterenol, n=14). *P<0.01 compared with Ad.ßgal-GFP.Phospholamban plays an important role in modulating the response to ß-adrenergic stimulus because its phosphorylation leads to increased ATPase activity10 and acceleration of both contraction and relaxation. Addition of isoproterenol in nonfailing cardiomyocytes enhanced contraction but also was associated with aftercontractions (data not shown). Ablation of phospholamban increased contraction and significantly decreased the time of contraction, as depicted in Figure 2B. With the substantial decrease in the time course of contraction in failing human cardiomyocytes infected with Ad.asPL, the addition of isoproterenol still had additive effects on the time course of contractions, as shown in Figure 2B.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study revealed important findings with regard to targeting calcium cycling proteins in failing human cardiomyocytes: (1) Decreasing phospholamban expression restores contractility in failing ventricular cells of different etiologies; and (2) ablation of phospholamban results in improvement in contractility similar to that of SERCA2a overexpression.
Studies by Kranias et al6,7 have shown clearly that murine models of phospholamban knockout have enhanced contractility. Furthermore, ablation of phospholamban prevented the development of heart failure and restored cardiac function in several murine models of heart failure, including muscle lim protein–knockout (MLP-/-) mice.11 Our results show that improving calcium cycling by decreasing phospholamban inhibition to SERCA2a restores contractility in failing human ventricular cardiomyocytes. These findings also extend previous results showing that overexpression of SERCA2a improves contractile function in human failing cardiac myocytes.
Even though the two strategies—phospholamban decrease and overexpression of SERCA2a—improved contractile function in the failing human cardiomyocytes to the same extent, there were certain differences. SERCA2a activity increased to a greater degree in cardiomyocytes overexpressing SERCA2a. In failing cardiomyocytes, relieving inhibition to SERCA2a pumps, which may be impaired because of oxidative stresses,12 may not restore ATPase activity to normal.
One concern about the strategy of increasing SERCA2a by diminishing phospholamban inhibition is the energy cost, which would be anticipated to increase ATP hydrolysis. Our group has recently shown that overexpression of SERCA2a in a rat model of heart failure enhances contractility without energetic compromise.13 In fact, in this model of heart failure, overexpression of SERCA2a restored the balance between ATP and creatine phosphate.
Another concern with the antisense approach is that it uncouples the ß-receptors from one of their downstream targets, phospholamban, rendering them "spare receptors." This would decrease the modulatory effects of isoproterenol. Interestingly, though, with phospholamban ablation, the contractile state of the cardiomyocyte at baseline is high. Furthermore, the human heart has only a small receptor reserve (if any) for ß-adrenoceptors.14,15 It is unclear from our study what the long-term effects of functionally increasing these spare receptors will be. Also, the ratio of the Na/Ca exchanger to SERCA2a has been shown to be increased in failing hearts and to be predictive of diastolic function in these hearts.16 Even though ablation of phospholamban would not affect the ratio of SERCA2a to Na/Ca, the resultant enhancement of SERCA2a activity would contribute to restoring diastolic function.
Our results demonstrate that targeting calcium regulation by ablation of phospholamban improves contractile function in failing human cardiomyocytes. This study validates the feasibility of cardiac gene transfer in failing hearts as a therapeutic modality.
|
Acknowledgments |
|---|
This work was supported in part by grants from the National Institutes of Health (HL 57623 to Dr Hajjar and HL 49574 to Dr Gwathmey) and the British Heart Foundation (Dr Harding) and by a Doris Duke Charitable Foundation Clinician Scientist Award (to Dr Hajjar). Dr Hajjar is a Beeson Scholar of the American Federation of Aging Research. The authors thank the cardiac surgeons at Massachusetts General Hospital and the National Disease Research Interchange.
Received November 13, 2001; revision received January 7, 2002; accepted January 8, 2002.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Gwathmey JK, Copelas L, MacKinnon R, et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res. 1987; 61: 70–76.
2.
Beuckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation. 1992; 85: 1046–1055.
3. Schmidt U, Hajjar RJ, Kim CS, et al. Human heart failure: cAMP stimulation of SR Ca(2+)-ATPase activity and phosphorylation level of phospholamban. Am J Physiol. 1999; 277: H474–H480.
4.
Schwinger RH, Bohm M, Schmidt U, et al. Unchanged protein levels of SERCAII and phospholamban but reduced Ca2+ uptake and Ca2+-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation. 1995; 92: 3220–3228.
5. Schwinger RH, Munch G, Bolck B, et al. Reduced Ca2+-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation. J Mol Cell Cardiol. 1999; 31: 479–491.[CrossRef][Medline] [Order article via Infotrieve]
6.
Koss KL, Kranias EG. Phospholamban: a prominent regulator of myocardial contractility. Circ Res. 1996; 79: 1059–1063.
7.
Luo W, Grupp IL, Harrer J, et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res. 1994; 75: 401–409.
8.
del Monte F, Harding SE, Schmidt U, et al. Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a. Circulation. 1999; 100: 2308–2311.
9.
He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998; 95: 2509–2514.
10. Tada M, Kirchberger MA, Katz AM. Regulation of calcium transport in cardiac sarcoplasmic reticulum by cyclic AMP-dependent protein kinase. Recent Adv Stud Cardiac Struct Metab. 1976; 9: 225–239.[Medline] [Order article via Infotrieve]
11. Minamisawa S, Hoshijima M, Chu G, et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell. 1999; 99: 313–322.[CrossRef][Medline] [Order article via Infotrieve]
12.
Xu KY, Zweier JL, Becker LC. Hydroxyl radical inhibits sarcoplasmic reticulum Ca(2+)-ATPase function by direct attack on the ATP binding site. Circ Res. 1997; 80: 76–81.
13.
del Monte F, Williams E, Lebeche D, et al. Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure. Circulation. 2001; 104: 1424–1429.
14. Schwinger RH, Bohm M, Erdmann E. Evidence against spare or uncoupled beta-adrenoceptors in the human heart. Am Heart J. 1990; 119: 899–904.[CrossRef][Medline] [Order article via Infotrieve]
15. Brown L, Deighton NM, Bals S, et al. Spare receptors for beta-adrenoceptor-mediated positive inotropic effects of catecholamines in the human heart. J Cardiovasc Pharmacol. 1992; 19: 222–232.[Medline] [Order article via Infotrieve]
16.
Hasenfuss G, Schillinger W, Lehnart SE, et al. Relationship between Na+-Ca2+-exchanger protein levels and diastolic function of failing human myocardium. Circulation. 1999; 99: 641–648.
This article has been cited by other articles:
 |
|
 |
|
  I. Vandecaetsbeek, M. Trekels, M. De Maeyer, H. Ceulemans, E. Lescrinier, L. Raeymaekers, F. Wuytack, and P. Vangheluwe Structural basis for the high Ca2+ affinity of the ubiquitous SERCA2b Ca2+ pump PNAS, November 3, 2009; 106(44): 18533 - 18538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Bupha-Intr, J. Laosiripisan, and J. Wattanapermpool Moderate intensity of regular exercise improves cardiac SR Ca2+ uptake activity in ovariectomized rats J Appl Physiol, October 1, 2009; 107(4): 1105 - 1112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Waggoner, K. S. Ginsburg, B. Mitton, K. Haghighi, J. Robbins, D. M. Bers, and E. G. Kranias Phospholamban overexpression in rabbit ventricular myocytes does not alter sarcoplasmic reticulum Ca transport Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H698 - H703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Antoons and K. R. Sipido Targeting calcium handling in arrhythmias Europace, December 1, 2008; 10(12): 1364 - 1369. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Gao, T. Tang, T. Guo, A. Miyanohara, T. Yajima, K. Pestonjamasp, J. R. Feramisco, and H. K. Hammond Adenylyl Cyclase Type VI Increases Akt Activity and Phospholamban Phosphorylation in Cardiac Myocytes J. Biol. Chem., November 28, 2008; 283(48): 33527 - 33535. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger Designing Heart Performance by Gene Transfer Physiol Rev, October 1, 2008; 88(4): 1567 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Vinge, P. W. Raake, and W. J. Koch Gene Therapy in Heart Failure Circ. Res., June 20, 2008; 102(12): 1458 - 1470. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Day, P. Coutu, W. Wang, T. Herron, I. Turner, M. Shillingford, N. C. LaCross, K. L. Converso, L. Piao, J. Li, et al. Cardiac-directed parvalbumin transgene expression in mice shows marked heart rate dependence of delayed Ca2+ buffering action Physiol Genomics, May 1, 2008; 33(3): 312 - 322. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Vanderheyden, W. Mullens, L. Delrue, M. Goethals, B. de Bruyne, W. Wijns, P. Geelen, S. Verstreken, F. Wellens, and J. Bartunek Myocardial Gene Expression in Heart Failure Patients Treated With Cardiac Resynchronization Therapy: Responders Versus Nonresponders J. Am. Coll. Cardiol., January 15, 2008; 51(2): 129 - 136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Periasamy, P. Bhupathy, and G. J. Babu Regulation of sarcoplasmic reticulum Ca2+ ATPase pump expression and its relevance to cardiac muscle physiology and pathology Cardiovasc Res, January 15, 2008; 77(2): 265 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-Y. Zhao, S.-J. Hu, J. Li, Y. Mou, K. Bian, J. Sun, and Z.-H. Zhu rAAV-asPLB transfer attenuates abnormal sarcoplasmic reticulum Ca2+-ATPase activity and cardiac dysfunction in rats with myocardial infarction Eur J Heart Fail, January 1, 2008; 10(1): 47 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Arvanitis, E. Vafiadaki, G.-C. Fan, B. A. Mitton, K. N. Gregory, F. Del Monte, A. Kontrogianni-Konstantopoulos, D. Sanoudou, and E. G. Kranias Histidine-rich Ca-binding protein interacts with sarcoplasmic reticulum Ca-ATPase Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1581 - H1589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Givertz, C. Andreou, C. H. Conrad, and W. S. Colucci Direct Myocardial Effects of Levosimendan in Humans With Left Ventricular Dysfunction: Alteration of Force-Frequency and Relaxation-Frequency Relationships Circulation, March 13, 2007; 115(10): 1218 - 1224. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Nordlie, L. E. Wold, B. Z. Simkhovich, C. Sesti, and R. A. Kloner Molecular Aspects of Ischemic Heart Disease: Ischemia/Reperfusion-Induced Genetic Changes and Potential Applications of Gene and RNA Interference Therapy Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2006; 11(1): 17 - 30. [Abstract] [PDF]
|
|
|
|
|
|
D. A. Kass Cardiac Resynchronization Therapy and Cardiac Reserve: How You Climb a Staircase May Alter Its Steepness Circulation, February 21, 2006; 113(7): 923 - 925. [Full Text] [PDF]
|
|
|
|
|
|
W. Zhao, Q. Yuan, J. Qian, J. R. Waggoner, A. Pathak, G. Chu, B. Mitton, X. Sun, J. Jin, J. C. Braz, et al. The Presence of Lys27 Instead of Asn27 in Human Phospholamban Promotes Sarcoplasmic Reticulum Ca2+-ATPase Superinhibition and Cardiac Remodeling Circulation, February 21, 2006; 113(7): 995 - 1004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Haghighi, F. Kolokathis, A. O. Gramolini, J. R. Waggoner, L. Pater, R. A. Lynch, G.-C. Fan, D. Tsiapras, R. R. Parekh, G. W. Dorn II, et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy PNAS, January 31, 2006; 103(5): 1388 - 1393. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Sipido and D. Eisner Something old, something new: Changing views on the cellular mechanisms of heart failure Cardiovasc Res, November 1, 2005; 68(2): 167 - 174. [Full Text] [PDF]
|
|
|
|
|
|
K. Berenji, M. H. Drazner, B. A. Rothermel, and J. A. Hill Does load-induced ventricular hypertrophy progress to systolic heart failure? Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H8 - H16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Ziolo, J. L. Martin, J. Bossuyt, D. M. Bers, and S. M. Pogwizd Adenoviral Gene Transfer of Mutant Phospholamban Rescues Contractile Dysfunction in Failing Rabbit Myocytes With Relatively Preserved SERCA Function Circ. Res., April 29, 2005; 96(8): 815 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pathak, F. del Monte, W. Zhao, J.-E. Schultz, J. N. Lorenz, I. Bodi, D. Weiser, H. Hahn, A. N. Carr, F. Syed, et al. Enhancement of Cardiac Function and Suppression of Heart Failure Progression By Inhibition of Protein Phosphatase 1 Circ. Res., April 15, 2005; 96(7): 756 - 766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Gao, T. Tang, T. Guo, S. Q. Sun, J. R. Feramisco, and H. K. Hammond Adenylyl Cyclase Type VI Gene Transfer Reduces Phospholamban Expression in Cardiac Myocytes via Activating Transcription Factor 3 J. Biol. Chem., September 10, 2004; 279(37): 38797 - 38802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Kass, J. G.F. Bronzwaer, and W. J. Paulus What Mechanisms Underlie Diastolic Dysfunction in Heart Failure? Circ. Res., June 25, 2004; 94(12): 1533 - 1542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. C. Hirsch, A. R. Borton, F. P. Albayya, M. W. Russell, R. G. Ohye, and J. M. Metzger Comparative analysis of parvalbumin and SERCA2a cardiac myocyte gene transfer in a large animal model of diastolic dysfunction Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2314 - H2321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-S. Armand and L. J De Windt Calcium cycling in heart failure: how the fast became too furious Cardiovasc Res, June 1, 2004; 62(3): 439 - 441. [Full Text] [PDF]
|
|
|
|
|
|
M. A Movsesian Altered cAMP-mediated signalling and its role in the pathogenesis of dilated cardiomyopathy Cardiovasc Res, June 1, 2004; 62(3): 450 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Frey, H. A. Katus, E. N. Olson, and J. A. Hill Hypertrophy of the Heart: A New Therapeutic Target? Circulation, April 6, 2004; 109(13): 1580 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Williams, J. A. Hata, J. Schroder, E. Rampersaud, J. Petrofski, A. Jakoi, C. A. Milano, and W. J. Koch Targeted {beta}-Adrenergic Receptor Kinase ({beta}ARK1) Inhibition by Gene Transfer in Failing Human Hearts Circulation, April 6, 2004; 109(13): 1590 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. MELO, A. S. PACHORI, D. KONG, M. GNECCHI, K. WANG, R. E. PRATT, and V. J. DZAU Gene and cell-based therapies for heart disease FASEB J, April 1, 2004; 18(6): 648 - 663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. W. Dorn II and J. D. Molkentin Manipulating Cardiac Contractility in Heart Failure: Data From Mice and Men Circulation, January 20, 2004; 109(2): 150 - 158. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Zhang, S. Miyamoto, and J. H. Brown Cardiomyocyte Calcium and Calcium/Calmodulin-dependent Protein Kinase II: Friends or Foes? Recent Prog. Horm. Res., January 1, 2004; 59(1): 141 - 168. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Lohse, S. Engelhardt, and T. Eschenhagen What Is the Role of {beta}-Adrenergic Signaling in Heart Failure? Circ. Res., November 14, 2003; 93(10): 896 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. W. Stevenson Clinical Use of Inotropic Therapy for Heart Failure: Looking Backward or Forward?: Part II: Chronic Inotropic Therapy Circulation, July 29, 2003; 108(4): 492 - 497. [Full Text] [PDF]
|
|
|
|
|
|
L. W. Stevenson Clinical Use of Inotropic Therapy for Heart Failure: Looking Backward or Forward? Part I: Inotropic Infusions During Hospitalization Circulation, July 22, 2003; 108(3): 367 - 372. [Full Text] [PDF]
|
|
|
|
|
|
S. Wiechert, A. El-Armouche, T. Rau, W. -H. Zimmermann, and T. Eschenhagen 24-h Langendorff-perfused neonatal rat heart used to study the impact of adenoviral gene transfer Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H907 - H914. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. G. Schwinger and K. F. Frank Calcium and the Failing Heart: Phospholamban, Good Guy or Bad Guy? Sci. Signal., April 29, 2003; 2003(180): pe15 - pe15. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. del Monte and R. J Hajjar Targeting calcium cycling proteins in heart failure through gene transfer J. Physiol., January 1, 2003; 546(1): 49 - 61. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Zhao, K. F Frank, G. Chu, M. J Gerst, A. G Schmidt, Y. Ji, M. Periasamy, and E. G Kranias Combined phospholamban ablation and SERCA1a overexpression result in a new hyperdynamic cardiac state Cardiovasc Res, January 1, 2003; 57(1): 71 - 81. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Chaudhri, F. del Monte, R. J. Hajjar, and S. E. Harding Interaction between increased SERCA2a activity and beta -adrenoceptor stimulation in adult rabbit myocytes Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2450 - H2457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G Schmidt, J. Zhai, A. N Carr, M. J Gerst, J. N Lorenz, P. Pollesello, A. Annila, B. D Hoit, and E. G Kranias Structural and functional implications of the phospholamban hinge domain: impaired SR Ca2+ uptake as a primary cause of heart failure Cardiovasc Res, November 1, 2002; 56(2): 248 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Wechsler, Y.-H. Choi, J. Krall, F. Ahmad, V. C. Manganiello, and M. A. Movsesian Isoforms of Cyclic Nucleotide Phosphodiesterase PDE3A in Cardiac Myocytes J. Biol. Chem., October 4, 2002; 277(41): 38072 - 38078. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||